Crispr Theraptc (NASDAQ:CRSP) had their “market perform” rating reissued by Equities research analysts at Oppenheimer Holdings, Inc. in a report issued on Tuesday, July 18th. Oppenheimer Holdings also issued estimates for Crispr Theraptc’s Q2 2017 earnings at ($0.62) EPS, Q3 2017 earnings at ($0.48) EPS, Q4 2017 earnings at ($0.77) EPS, FY2017 earnings at ($2.42) EPS, Q1 2018 earnings at ($0.68) EPS, Q2 2018 earnings at ($0.81) EPS, Q3 2018 earnings at ($0.62) EPS, Q4 2018 earnings at ($1.00) EPS, FY2018 earnings at ($3.11) EPS, FY2019 earnings at ($2.73) EPS, FY2020 earnings at ($4.34) EPS and FY2021 earnings at ($5.36) EPS.
Several other equities research analysts have also issued reports on CRSP. Chardan Capital started coverage on Crispr Theraptc in a research report on Monday, March 27th. They set a “buy” rating and a $23.50 target price for the company. SunTrust Banks, Inc. started coverage on Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 target price for the company. Finally, Cann started coverage on Crispr Theraptc in a report on Monday, July 17th. They issued a “market perform” rating for the company. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $21.92.
Shares of Crispr Theraptc (CRSP) traded up 2.39% during midday trading on Tuesday, hitting $19.68. 262,947 shares of the stock were exchanged. The firm’s market capitalization is $785.13 million. Crispr Theraptc has a 1-year low of $11.63 and a 1-year high of $25.00. The stock’s 50-day moving average price is $17.08 and its 200-day moving average price is $17.49.
Crispr Theraptc (NASDAQ:CRSP) last announced its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative return on equity of 53.86% and a negative net margin of 406.61%. The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. The firm’s quarterly revenue was up 350.0% on a year-over-year basis. On average, analysts forecast that Crispr Theraptc will post ($2.46) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Crispr Theraptc (CRSP) Given “Market Perform” Rating by Oppenheimer Holdings, Inc. Analysts” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/14/crispr-theraptc-crsp-given-market-perform-rating-by-oppenheimer-holdings-inc-analysts-updated-updated-updated.html.
In related news, Director Kurt Von Emster sold 81,435 shares of Crispr Theraptc stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $17.08, for a total value of $1,390,909.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rodger Novak sold 3,650 shares of Crispr Theraptc stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $15.02, for a total value of $54,823.00. Following the completion of the sale, the chief executive officer now directly owns 1,218,655 shares of the company’s stock, valued at approximately $18,304,198.10. The disclosure for this sale can be found here. In the last three months, insiders sold 543,814 shares of company stock valued at $9,232,047. 39.98% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. IHT Wealth Management LLC bought a new position in Crispr Theraptc during the first quarter worth $110,000. Wells Fargo & Company MN raised its position in Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares during the last quarter. ARK Investment Management LLC bought a new position in Crispr Theraptc during the second quarter worth $206,000. Vanguard Group Inc. bought a new position in Crispr Theraptc during the second quarter worth $273,000. Finally, Monashee Investment Management LLC raised its position in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the last quarter. 24.08% of the stock is owned by institutional investors and hedge funds.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.
